FDA Oks Pricey New Cholesterol Drug For Certain Patients

Features FOXBusiness

Praluent carries an estimated price tag between $7,000 and $12,000 per year, according to Medical Marketing & Media. The companies have not formally confirmed the cost. However analysts estimate it will be the most costly cholesterol drug on the market. FOXBusiness.com takes a look at how the drug may stack up against more established treatments. 

Continue Reading Below

  • 1. The Praluent Push is Responsible for Regeneron's 2015 Rally

    The Praluent Push is Responsible for Regeneron's 2015 Rally

    Regeneron's (REGN) stock price has soared 35% this year as investors bet cholesterol drug Praluent will eventually hit blockbuster status with sales of at least $1 billion. But the drug is facing some long established rivals...

     

  • 2. Crestor

    Crestor

    AstraZeneca (AZN) manufactures this well-known lipid regulator, which raked in a whopping $5,848,160,064 in sales in 2014.

  • 3. Zetia

    Zetia

    Merck (MRK) blockbuster drug, Zetia pulled in $2,036,844,880 and is one of two drugs on the list to cross the billion-dollar mark in sales.

  • 4. Fenofibrate

    Fenofibrate

    This generic drug, which falls under several brand names including Antara and Lipofen, reached $836,923,449 in 2014 sales.

  • 5. Vytorin

    Vytorin

    Another lucrative drug for Merck (MRK) which posted $774,222,194 in sales in 2014.

  • 6. Generic Lipitor

    Generic Lipitor

    The atorvastatin calcium drug, which is manufactured by Pfizer (PFE), raked in $729,693,375 in 2014 sales. At one time the drug was the leading cholesterol treatment before its patent expired in November 2011. 

Continue Reading Below

What do you think?

Click the button below to comment on this article.